normative

Finch sequences C. diff as its first proven indication

Finch chose C. difficile as its first indication because the company had experience serving those patients, and proving efficacy there creates a revenue floor that funds bigger bets in ulcerative colitis, Crohn's, and oncology.

normativepending

Speaker

Mark Smith

Evidence Quote

“We saw C. diff as creating a floor value in the company where we know it works there. We know we can serve patients and have a reliable revenue stream.”

Source

Finch Therapeutics: Empowering Immune Systems— Business Breakdowns
Created: 11/16/2026, 7:13:42 PM

Your notes

Loading notes...